Abstract:Abstract Background Infliximab (IFX) and Adalimumab (ADA) are effective treatments for managing Inflammatory Bowel Disease (IBD) but treatment failure is common. Therapeutic drug monitoring (TDM) of trough serum drug concentrations (C Trough) has been used to optimize treatment induction, mitigate immunogenicity, and ensure appropriate drug exposure. HLA DQA1*05 genotype variants have been identified as predictors of immunogenicity. This study aimed to investigate the impact of dashboard-guided optimized induction dosing strategy on clinical and pharmacokinetics outcomes of anti-TNF, with the goal of analysing the HLA DQA1*05 effect. Methods We conducted a retrospective single-centre cohort analysis of IBD patients, Crohn’s disease (CD) and Ulcerative Colitis (UC), who initiated treatment with IFX or ADA between January 2020 and March 2023, using a pharmacokinetic dashboard-guided induction, protocolized with the Pharmacy Department. C Trough measurements were taken at week 2, 6 and 14, first drug intervention based on the model was in week 4. Targeted C Trough levels during induction were set at 10-15 mcg/mL for ADA and > 17 mcg/mL for IFX. Primary objective was to assess clinical remission (CR). Secondary outcomes included treatment failure (TF) and endoscopic remission (ER). We performed a descriptive analysis and generated Kaplan Meier curves to assess drug survival Results We enrolled 147 patients, 92 having CD (74 treated with ADA and 18 with IFX) and 55 having UC (36 treated with ADA and 19 CU with IFX). HLA DQA1*05 genotype variant was present in 44,14% of patients. Combined treatment with thiopurine was used in 45,58% and 11,54% had been previously received biologic treatment. After 24 weeks, 91,83% (135/147) of patients achieved CR and 65,81% (77/117) at week 56. ER was observed in 59,84% (76/127) after a year. Anti-TNF drug survival probability was 85% after a year, meanwhile ADA drug survival in UC patients was 75%. A 77,7% of patients were prescribed an accelerated dose in the first year, which was associated with improved drug durability. Only a patient out of 147 developed antibodies to ADA. The HLA DQA1*05 variant was not a statistically significant predictor of adverse treatment or pharmacokinetic outcomes. Conclusion Optimizing anti-TNF induction with a Dashboard-guide dosing strategy proves to be a valuable approach to enhance clinical remission and durability rates in IBD patients. The role of HLADQA1*05 variant in immunogenicity appears to be mitigated by the model.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: How to improve the clinical efficacy and pharmacokinetic effects of anti - tumor necrosis factor (anti - TNF) drugs in the treatment of inflammatory bowel disease (IBD) through the optimization of induction - dose strategies guided by the dashboard. Specifically, the study aims to analyze the impact of HLA DQA1*05 genotype variation on the treatment effect, and explore whether this optimization strategy can improve the clinical remission rate of patients, reduce treatment failure, and enhance drug persistence. ### Background Infliximab (IFX) and Adalimumab (ADA) are effective treatments for managing IBD, but treatment failure is common. By monitoring the serum trough drug concentration ($C_{\text{Trough}}$), the treatment induction phase can be optimized, immunogenicity can be reduced, and appropriate drug exposure can be ensured. Studies have shown that HLA DQA1*05 genotype variation is a predictor of immunogenicity. ### Research Objectives The main objective of this study is to evaluate the impact of the dashboard - guided optimized induction - dose strategy on clinical remission (CR) in IBD patients. Secondary objectives include evaluating treatment failure (TF) and endoscopic remission (ER) and analyzing the role of HLA DQA1*05 genotype variation. ### Methods The study retrospectively analyzed IBD patients (including Crohn's disease and ulcerative colitis) who started treatment with IFX or ADA in a single center from January 2020 to March 2023. Through pharmacokinetic dashboard guidance, drug trough concentrations were measured at week 2, week 6, and week 14. The target trough concentrations were set as follows: ADA 10 - 15 μg/mL, IFX > 17 μg/mL. The primary endpoint was clinical remission, and the secondary endpoints included treatment failure and endoscopic remission. Drug survival was evaluated by Kaplan - Meier curves. ### Results A total of 147 patients were included, of which 92 were patients with Crohn's disease (74 using ADA, 18 using IFX), and 55 were patients with ulcerative colitis (36 using ADA, 19 using IFX). 44.14% of the patients carried HLA DQA1*05 genotype variation. After 24 weeks of treatment, 91.83% of the patients achieved clinical remission; at 56 weeks, 65.81% of the patients still maintained clinical remission. One year later, endoscopic remission was observed in 59.84% of the patients. The one - year survival probability of anti - TNF drugs was 85%, and the one - year survival rate of ADA in patients with ulcerative colitis was 75%. 77.7% of the patients received an accelerated dose within the first year, which was associated with an improvement in drug persistence. Only one patient developed antibodies against ADA. HLA DQA1*05 genotype variation was not proven to be a significant predictor of adverse treatment outcomes or pharmacokinetic outcomes. ### Conclusions The dashboard - guided optimized anti - TNF induction - dose strategy can significantly improve the clinical remission rate and drug persistence in IBD patients. The role of HLA DQA1*05 genotype variation in this model seems to be weakened. Through this method, researchers hope to provide more effective personalized treatment plans for IBD patients, thereby improving their long - term prognosis.

P668 Dashboard-guided anti-TNF induction as an effective proactive strategy in Inflammatory Bowel Disease's treatment

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

P337 Proactive therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome and persistence of treatment

P251 Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease

P353 Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment

P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease

P1070 Utilization of HLA-DQA1*05 haplotype testing in routine clinical practice to stratify advanced therapies: A prospective pilot study

P677 The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD): Analysis of 40,000 Patient Years of Anti-TNF Use

P815 Infliximab drug monitoring: proactive or reactive: a North West England NHS 3 trust retrospective study

Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease

Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease

P863 Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients

Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis

P918 Can we rely on HLA to predict resistance to biological therapy in Inflammatory Bowel Disease patients?

P611 Relation between AntiTNF levels during the induction and clinical and radiological outcomes in perianal Crohn ́s disease

P468 Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations

P960 Comparison of clinical outcomes by induction therapy response status in patients with Inflammatory Bowel Disease (IBD) treated with subcutaneous (SC) versus intravenous (IV) infliximab (IFX): Post hoc analysis of a pivotal, randomised controlled trial

P1038 Does combination immunomodulator therapy impact real-world biologic effectiveness in Inflammatory Bowel Diseases?A propensity score analysis in patients treated with anti-TNF and non-anti-TNF biologics in the UK IBD BioResource

P583 Infliximab Monitoring in Crohn's Disease and Development of Neural Networks Using Clinical Variables to Predict Disease Activity and Immunogenicity

P770 Proactive Infliximab monitoring improves the rates of transmural remission in Crohn’s disease – a propensity score matched analysis

P686 Comparison between therapeutic sequences starting with IV induction-biologic versus SC-induction biologic in bionaïve-patients with ulcerative colitis: results from the APPETISER study